Subscribe or Manage Preferences
The results of a systematic review support the interchangeability of biosimilar tumor necrosis factorα (TNF)-α inhibitors with their respective reference biologics in treating rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
The first biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin.
London, United Kingdom—Monitoring antidrug antibody formation in those receiving biologic disease-modifying antirheumatic drugs can inform treatment decisions in patients with rheumatic diseases. In particular, patients who developed antibodies to infliximab (Remicade) cross-reacted with the infliximab biosimilar CT-P13—marketed as Remsima or Inflectra—according to data from a multicenter, controlled study of patients with rheumatoid arthritis (RA) and spondylo­arthritis (SpA) presented at the 2016 European League Against Rheumatism Annual Congress.

Results 1 - 3 of 3
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology